A single arm, multicenter, open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) in participants who completed the parent Lp(a)HORIZON trial (CTQJ230A12301E1)

未提供0 个研究点目标入组 100 人开始时间: 待定

适应症

试验速览

暂无简介。

•Participants who have provided informed consent prior to initiation of any study-specific activities/procedures.
•Participants who have completed the parent study EOS visit while still on assigned investigational product.

•Participants who for any reason permanently discontinued or have interrupted the investigational product for continuous 6 months at EOS during the parent study.
•Participants who have a history or evidence of any clinically significant disorder, condition, or disease that in the opinion of the investigator or Novartis physician (if consulted), would put the participant at risk or interfere with the study participation.
•Participants are receiving another investigational drug or device before the open-label treatment period.
•Participants have a known sensitivity to the study drug and are deemed as unsuited for the study by the Investigator at Screening visit.

发起方

未提供